Adelphi Research Semaglutide 10mg Vial

Adelphi Research Semaglutide 10mg vial is a purified GLP-1 receptor agonist designed for research into appetite suppression, insulin response, and fat metabolism. As part of the latest generation of peptide-based therapies, this compound mimics the body's natural glucagon-like peptide-1 activity to support studies in weight regulation and metabolic efficiency.

Backed by the scientific legacy of Adelphi Research, this formulation is produced under sterile conditions and undergoes extensive quality verification. It is a top-tier choice for laboratories conducting GLP-1 peptide trials and pre-clinical evaluations.

Peptide Profile:

• Compound: Semaglutide (GLP-1 analog)
• Form: Injectable, subcutaneous
• Purity: ≥98%
• Use Case: Weight management, appetite modulation, metabolic health

How To Use Adelphi Semaglutide:

• Start with 0.25–0.5 mg per week
• Gradually increase to 1–2 mg per week based on tolerance
• Cycle Length: 8–16 weeks, with a 4-week break after each cycle
• Administration: Subcutaneous injection, once a week

Stacking suggestions: Pair with Synedica Tirzepatide or Retatrutide for combined GLP-1/GIP modulation pathways in metabolic testing environments.

Hygen Semaglutide or Viogen Semaglutide for a milder, maintenance dose